Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

BACKGROUND: Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%–50%) has been reported during pregnancy, but limited data on unbound exposure are available. OBJECTIVES: To eva...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Antimicrob Chemother
Main Authors: Schalkwijk, Stein, ter Heine, Rob, Colbers, Angela, Capparelli, Edmund, Best, Brookie M, Cressey, Tim R, Greupink, Rick, Russel, Frans G M, Moltó, José, Mirochnick, Mark, Karlsson, Mats O, Burger, David M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477987/
https://ncbi.nlm.nih.gov/pubmed/30715324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky567
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados